PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of mconcolMolecular & Cellular Oncology
 
Mol Cell Oncol. 2014 Oct-Dec; 1(4): e969626.
Published online 2014 November 11. doi:  10.4161/23723548.2014.969626
PMCID: PMC4905218

Porcine cancer models for translational oncology

Abstract

Large-animal cancer models are needed to advance the development of innovative and clinically applicable tumor diagnostic, therapeutic, and monitoring technologies. We developed a genetically modified porcine model of cancer based on a TP53 mutation, and established its utility for tracking tumorigenesis in vivo through non-invasive clinical imaging approaches.

The p53 tumor suppressor, encoded by the TP53 gene, is vital for cancer prevention. Considered the guardian of the genome, p53 responds to genotoxic stresses by transcriptionally regulating numerous genes that suppress cancer initiation and progression.2 More than half of all human tumors have sporadic mutations of TP53 and the overall risk of cancer in people with inherited TP53 mutation is exceedingly high.3

In the study by Sieren et al.1 the porcine TP53 gene was mutated in Yucatan miniature pigs, resulting in the first gene-targeted large-animal model of cancer. The porcine TP53 mutation (R167H) used is orthologous to a naturally occurring mutation found in many human cancers.4 Characterization of tumorigenesis in homozygous (TP53R167H/R167H) and heterozygous (TP53R167H/+) pigs was facilitated by clinical imaging technology, including computed tomography (CT) and magnetic resonance imaging (MRI). Non-invasive medical imaging successfully detected solid tumors, in addition to guiding tissue harvest for histopathological validation and molecular genetic analyses. TP53R167H/R167H pigs developed a variety of cancers during early phenotypic evaluation (within1,5 years of birth) including lymphoma, osteogenic tumors (osteosarcoma), and Wilms tumor (nephroblastoma). As predicted from studies of the analogous p53 mutation in mice (R172H) and humans (R175H), the porcine p53-R167H protein failed to mediate protective checkpoint responses in cells and promoted significant chromosomal instability in tumors from TP53R167H/R167H pigs. By comparison, no solid tumors have been detected in TP53R167H/+ pigs during 2.5 years of observation, which makes them highly suited to testing the cooperative effects of secondary oncogene activation or tumor suppressor gene loss. Indeed, TP53 mutant pigs represent a valuable platform on which to build new large-animal cancer models. The next milestone for porcine cancer models will be targeted tumor formation through conditional and/or tissue-specific expression of mutant cancer genes, either alone or added to a primed TP53R167H/+ background.5-7

Importantly, TP53 mutant pigs and other future porcine tumor models provide an unparalleled opportunity to impact cancer management in humans. For example, pigs allow the development and validation of new diagnostic, monitoring, and treatment approaches that employ clinical technology in an animal cancer model that is a comparable size to humans (Fig. 1). At maturity, Yucatan pigs reach a body weight of 60–75 kg, and have a thoracic and abdominal structure similar to that of an adult human, enabling these animals to be imaged by clinical instruments used for humans. The small size of rodents prevents mouse cancer models from being useful for direct translation of techniques requiring clinical technologies (CT, MR, minimally invasive surgical techniques, and/or radiation therapy). Additionally, pigs have a lifespan, circulatory volume, and metabolic/heart/respiratory rate in concordance with that of humans. Another advantage is that research using porcine cancer models can be performed in tightly controlled populations, without co-morbidities, and with or without therapeutic intervention, which is not possible in human cancer patients.

Figure 1.
Porcine cancer models provide unique opportunities to advance a number of key translational cancer research areas (examples are listed), which in turn would impact clinical cancer management for human patients. We have reported tumorigenesis in TP53R167H/R167H ...

As outlined in Figure 1, there is tremendous potential for improving clinical cancer management as a result of research using porcine cancer models. This is true not only for diagnostic imaging, but also for surgical and radiation treatments with accompanying response monitoring. Cross comparison of multiple imaging modalities and/or many variations of data acquisition parameters within a given modality on the same cancer subject is possible with the porcine cancer model. In addition, valuable advancements may be made in utilizing medical imaging to probe early pre-cancerous changes and to follow tumor formation and growth over time in the presence or absence of intervention. One of the current clinical challenges in cancer management is the optimal time for post-treatment positron emission tomography (PET) to detect remaining cancer in patients who have undergone radiation therapy while avoiding false positive signals caused by the inflammatory response.8 Development and validation of novel radiation therapy and imaging strategies will be assisted by porcine cancer models because of their similar anatomy to humans and the unrestricted ability to collect biospecimens for confirmatory analyses. Moreover, we envision the porcine cancer model being useful as both a developmental and educational tool for surgeons, enabling them to optimize techniques for complex surgeries (e.g., the Whipple procedure for pancreatic cancer) and/or novel cancer resection techniques. Notably, the impact of surgery on porcine cancer models with and without alternate neoadjuvant or adjuvant therapies could be studied in a controlled cohort.9

Cancer is a complex disease for which targeted therapies based on the unique genetic makeup of each patient and their tumors may yield optimal treatment outcomes. Biomarkers, specific factors, or molecular alterations that predict tumor development (diagnostic), survival (prognostic), and response to therapy (predictive), are the key to personalizing anticancer treatments. Comprehensive genetic and proteomic analyses of tumors from porcine cancer models, followed by cross-species comparisons to molecular data obtained from human and mouse tumors, should facilitate identification of commonly altered genes, RNAs, and/or proteins essential for tumorigenesis. This integrated approach could streamline the discovery of meaningful cancer biomarkers, which can be characterized and corroborated in porcine tumor models prior to their testing and confirmation in the clinic. Such information should ultimately help stratify cancer patients for enrollment in new clinical trials and for treatment with the most appropriate therapies and doses, thereby improving patient survival and quality of life.

Our understanding of human diseases has been profoundly advanced by animal models. Although mice have traditionally served as useful cancer models, large animals such as pigs have been indispensable in studying other pathologies such as cystic fibrosis.10 The unique translational capabilities of pigs for cancer research, as revealed by the porcine TP53 mutant study, will ideally stimulate additional development and study of porcine tumor models in the coming decade.

Disclosure of Potential Conflict of Interest

Christopher S. Rogers in an employee of Exemplar Genetics, a company that has applied for a patent related to the work reported herein. Jessica C. Sieren, Dawn Quelle and David K. Meyerholz have no conflicts of interest.

References

1. Sieren JC., Meyerholz DK., Wang XJ., Davis BT., Newell JD., Jr., Hammond E., Rohret JA., Rohret FA., Struzynski JT., Goeken JA, et al. Development and translational imaging of a TP53 porcine tumorigenesis model. J Clin Invest 2014; PMID:25105366 [PMC free article] [PubMed]
2. Levine AJ., Oren M.. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749-758; PMID:19776744; http://dx.doi.org/10.1038/nrc2723 [PMC free article] [PubMed] [Cross Ref]
3. Nichols KE., Malkin D., Garber JE., Fraumeni JF., Jr., Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol, Biomarkers Preven 2001; 10:83-87. [PubMed]
4. Petitjean A., Achatz MI., Borresen-Dale AL., Hainaut P., Olivier M.. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26:2157-2165; PMID:17401424; http://dx.doi.org/10.1038/sj.onc.1210302 [PubMed] [Cross Ref]
5. Hingorani SR., Wang L., Multani AS., Combs C., Deramaudt TB., Hruban RH., Rustgi AK., Chang S., Tuveson DA.. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469-483; PMID:15894267; http://dx.doi.org/10.1016/j.ccr.2005.04.023 [PubMed] [Cross Ref]
6. Xue W., Chen S., Yin H., Tammela T., Papagiannakopoulos T., Joshi NS., Cai W., Yang G., Bronson R., Crowley DG, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 2014. [PMC free article] [PubMed]
7. Walkley CR., Qudsi R., Sankaran VG., Perry JA., Gostissa M., Roth SI., Rodda SJ., Snay E., Dunning P., Fahey FH, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008; 22:1662-1676; PMID:18559481; http://dx.doi.org/10.1101/gad.1656808 [PubMed] [Cross Ref]
8. Bussink J., Kaanders JH., van der Graaf WT., Oyen WJ.. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nature reviews. Clin Oncol 2011; 8:233-242; PMID:21263464 [PubMed]
9. Paulson AS., Tran Cao HS., Tempero MA., Lowy AM.. Therapeutic advances in pancreatic cancer. Gastroenterology 2013; 144:1316-1326; PMID:23622141; http://dx.doi.org/10.1053/j.gastro.2013.01.078 [PubMed] [Cross Ref]
10. Rogers CS., Stoltz DA., Meyerholz DK., Ostedgaard LS., Rokhlina T., Taft PJ., Rogan MP., Pezzulo AA., Karp PH., Itani OA, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008; 321:1837-1841; PMID:18818360; http://dx.doi.org/10.1126/science.1163600 [PMC free article] [PubMed] [Cross Ref]

Articles from Molecular & Cellular Oncology are provided here courtesy of Taylor & Francis